| |
Research Description:
The Lazo laboratory is primarily focusing on studying how enzymes that remove high energy phosphates from proteins controlling cell division, migration and survival using both molecular biological and pharmacological approaches. Other major themes include determining the mechanism of action of new anticancer agents and the development of both high through and high content screens of small molecule chemical libraries. 
Education:
B.A. (Chemistry), Johns Hopkins University, 1971.
Ph.D. (Pharmacology), University of Michigan, 1976.
Postdoctoral Fellow, Yale University School of Medicine, 1976-1978.
Important Publications:
- Achiwa H and JS Lazo. PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Res. 67:643-650, 2007
- Bansal P and JS Lazo. Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. Cancer Res. 67:3356-3363, 2007
- Panchal RG, G Ruthel, KC Brittingham, D Lane, TA Kenny, R Gussio, JS Lazo and S Bavari. Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis. Chem Biol 14:245-255, 2007
- Tierno MB, PA Johnston, C Foster, JJ Skoko, SN Shinde, TY Shun and JS Lazo. Development and optimization of high-throughput in vitro protein phosphatase screening assays. Nature Protocols 2:1134-1144, 2007
- Lyon MA, AP Ducruet, P Wipf and JS Lazo. Dual-specificity phosphatases as targets for antineoplastic agents. Nature Reviews Drug Discov 1:961-976, 2002
- Schwartz DR, GE Homanics, DG Hoyt, E Klein, J Abernethy and JS Lazo. The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance. Proc Natl Acad Sci USA 96:4680-4685, 1999
- Kelley SL, A Basu, BA Teicher, MP Hacker, DH Hamer and JS Lazo. Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813-1815, 1998
|
